Working Group 4
Policy Regulation and Impact Analysis Across Europe
wORKING GROUP 4
Policy Regulation and Impact Analysis Across Europe
Working Group 4 addresses the regulatory, economic, and policy dimensions of pharmacogenomics implementation in cardiovascular care. The group analyzes existing frameworks across European countries and identifies barriers to harmonization and large-scale adoption.
Prof. Damir Marjanović
Institute for Anthropological Research
damir.marjanovic@inantro.hr
A key focus is the evaluation of the economic impact of PGx, including potential cost savings from reduced adverse drug reactions and improved therapy outcomes. WG4 also examines regulatory guidelines, data-sharing challenges, and cross-border collaboration requirements.
Through policy recommendations and stakeholder engagement, this working group supports the development of a unified European approach to pharmacogenomics, ensuring equitable access and sustainable integration into healthcare systems.
Write a clear and relevant header to keep your visitors engaged
TASK 4.1
Impact analysis of economics of PGx
TASK 4.2
Country-wise review of present guidelines
TASK 4.3
Authority and guidelines under the EMA competence
TASK 4.4
Data sharing across the EU countries and non-EU member countries
TASK 4.5
Stakeholder engagement